Investors & Media

Webcast ImageWebcast
Annual Stockholder Meeting & Open House (Replay)
05/24/17 at 2:00 p.m. PT
Annual Stockholder Meeting & Open House
Wednesday, May 24, 2017 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
Recent Press ReleasesMore >>
05/25/17Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the publication in The New England Journal of Medicine of key preclinical findings with angiopoietin-like 3 (ANGPTL3)-targeting drugs and Phase 1/2 clinical study results with AKCEA-ANGPTL3-LRx (formerly IONIS-ANGPTL3-LRx). In the Phase 1/2 clinical study, treatment with AKCEA-ANGPTL3-LRx resulted in substantial, dose-dependent reductions in ... 
05/15/17Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Webcast to Discuss Results May 15, 2017 at 8:30 am ET CARLSBAD, Calif., May 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the Phase 3 NEURO-TTR study of inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints. Over the 15-month period of the study, inotersen-treated patients achieved statistically significant benefit compared to placebo in the modified Neuropathy Impairment Score +7 (mNIS+... 
05/11/17Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders
CARLSBAD, Calif., May 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that management will present a general corporate update in conjunction with its 2017 Annual Meeting of Stockholders and Open House on Wednesday, May 24 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA. The agenda for the meeting is as follows: 2:00 p.m. – 2:10 p.m. PT – Annual Meeting of Stockholders (for stockholders of record as o... 
05/10/17Ionis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
CARLSBAD, Calif., May 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present at the Bank of America Merrill Lynch 2017 Healthcare Conference at 9:20 a.m. Pacific Time on Wednesday, May 17, 2017 in Las Vegas, NV. A live webcast of the presentation will be available on the "Investors & Media" section of the Ionis website at The replay will b... 
Upcoming EventsMore >>
There are currently no events scheduled.

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.